Ubs Group Ag Vyne Therapeutics Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$0.12 - $4.91 $5,306 - $217,105	44,217 Added 422.85%	54,674 $8,000
Q3 2022 Nov 10, 2022	SELL	$0.24 - $4.27 $2 - $51	-12 Reduced 0.11%	10,457 $2,000
Q2 2022 Aug 10, 2022	BUY	$0.37 - $0.71 $3,779 - $7,251	10,214 Added 4005.49%	10,469 $4,000
Q1 2022 May 16, 2022	BUY	$0.5 - $1.15 $6 - $13	12 Added 4.94%	255 $0
Q4 2021 Feb 14, 2022	SELL	$0.91 - $1.5 $3,458 - $5,701	-3,801 Reduced 93.99%	243 $0
Q3 2021 Nov 15, 2021	SELL	$1.39 - $3.47 $4,502 - $11,239	-3,239 Reduced 44.47%	4,044 $6,000
Q2 2021 Aug 13, 2021	BUY	$3.24 - $6.92 $2,028 - $4,331	626 Added 9.4%	7,283 $26,000
Q1 2021 May 12, 2021	BUY	$6.34 - $12.68 $42,205 - $84,410	6,657 New	6,657 $46,000

36.5K

Ticker VYNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,005,600
Market Cap $170M
Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.